Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 385,532,672
  • Shares Outstanding, K 2,407,623
  • Annual Sales, $ 85,159 M
  • Annual Income, $ 35,153 M
  • EBIT $ 13,952 M
  • EBITDA $ 21,438 M
  • 60-Month Beta 0.52
  • Price/Sales 4.52
  • Price/Cash Flow 11.70
  • Price/Book 5.49

Options Overview Details

View History
  • Implied Volatility 18.63% ( +0.09%)
  • Historical Volatility 12.20%
  • IV Percentile 87%
  • IV Rank 61.27%
  • IV High 22.48% on 08/05/24
  • IV Low 12.53% on 05/09/24
  • Put/Call Vol Ratio 0.43
  • Today's Volume 35,513
  • Volume Avg (30-Day) 25,579
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 336,729
  • Open Int (30-Day) 362,136

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 2.04
  • Number of Estimates 7
  • High Estimate 2.33
  • Low Estimate 1.94
  • Prior Year 2.29
  • Growth Rate Est. (year over year) -10.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
158.07 +0.11%
on 11/04/24
166.75 -5.10%
on 10/15/24
-2.05 (-1.28%)
since 10/04/24
3-Month
156.44 +1.15%
on 08/13/24
168.85 -6.28%
on 09/04/24
-5.90 (-3.59%)
since 08/02/24
52-Week
143.13 +10.56%
on 04/18/24
168.85 -6.28%
on 09/04/24
+6.90 (+4.56%)
since 11/03/23

Most Recent Stories

More News
1 Outstanding AI Growth Stock to Grab Now

AI could soon transform the medical technology industry, and this market leader may continue to dominate.

$SPX : 5,712.69 (-0.28%)
JNJ : 158.24 (-1.18%)
MDT : 89.31 (-0.84%)
ISRG : 507.42 (+0.21%)
3 Dividend Growth Stocks You Can Buy and Hold Forever

These healthcare stocks have fantastic dividend track records.

ABT : 117.65 (-0.80%)
JNJ : 158.24 (-1.18%)
ABBV : 200.47 (-1.51%)
Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?

AbbVie ABBV is set to report third-quarter earnings on Oct. 30, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $14.28 billion and $2.93 per share, respectively.The...

NVO : 109.72 (-1.98%)
JNJ : 158.24 (-1.18%)
LLY : 806.14 (-1.56%)
ABBV : 200.47 (-1.51%)
RHHBY : 39.4300 (+0.43%)
Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government

In 1980, around five dozen publicly traded companies held the highest possible credit rating (AAA) from Standard & Poor's. Today, there are only two left.

MSFT : 408.46 (-0.47%)
JNJ : 158.24 (-1.18%)
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime

These three Vanguard ETFs are worth considering for the long term.

GOOGL : 169.24 (-1.20%)
AAPL : 222.01 (-0.40%)
AVGO : 168.55 (-0.22%)
JPM : 219.78 (-1.42%)
JNJ : 158.24 (-1.18%)
VTI : 281.72 (-0.18%)
BRK.AX : 0.440 (+1.15%)
UNH : 557.77 (-1.72%)
MSFT : 408.46 (-0.47%)
TSLA : 242.84 (-2.47%)
V : 291.85 (+0.38%)
LLY : 806.14 (-1.56%)
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock

Fewer contenders means fewer constraints on expanding market share.

JNJ : 158.24 (-1.18%)
LLY : 806.14 (-1.56%)
BIIB : 173.52 (-0.16%)
The Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi

For Immediate ReleaseChicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

JNJ : 158.24 (-1.18%)
ABBV : 200.47 (-1.51%)
RHHBY : 39.4300 (+0.43%)
PFE : 27.76 (-1.17%)
SNY : 52.95 (-0.60%)
Stock market today: Wall Street pulls back from its records

U.S. stocks edged back from their all-time highs as some of the steam came out of Wall Street’s long, record-breaking rally

NFLX : 755.51 (-0.08%)
KO : 65.11 (+0.15%)
T : 21.92 (-0.90%)
LEN : 172.63 (+1.75%)
IBM : 206.32 (-0.93%)
$SPX : 5,712.69 (-0.28%)
GM : 51.80 (+1.65%)
JNJ : 158.24 (-1.18%)
KVUE : 23.04 (+1.36%)
$DOWI : 41,794.60 (-0.61%)
$IUXX : 19,963.60 (-0.35%)
BA : 155.07 (+0.31%)
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale

Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in its consumer healthcare (CHC)...

JNJ : 158.24 (-1.18%)
GSK : 36.97 (+0.24%)
PFE : 27.76 (-1.17%)
SNY : 52.95 (-0.60%)
All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year

Investors looking for dividend stocks at reasonable valuations have come to the right place.

CVX : 153.97 (+0.59%)
JNJ : 158.24 (-1.18%)
$DOWI : 41,794.60 (-0.61%)
DOW : 47.95 (-2.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 161.87
2nd Resistance Point 161.07
1st Resistance Point 159.66
Last Price 158.24
1st Support Level 157.45
2nd Support Level 156.65
3rd Support Level 155.24

See More

52-Week High 168.85
Fibonacci 61.8% 159.02
Last Price 158.24
Fibonacci 50% 155.99
Fibonacci 38.2% 152.96
52-Week Low 143.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar